CHA 의과학대학교 분당차병원 임상시험센터

핵심인력

항암 면역 세포치료제 연구팀

항암 면역세포치료제 연구팀은 난소암, 유방암 등 다양한 여성암의 발암, 항암제내성 기전연구 및 암 정복 치료제 개발 연구를 수행해왔으며, 현재 면역세포치료제 R&BD 개발에 힘쓰고 있습니다. 이 과정에서 다양한 암세포에 대한 효능평가를 수행하면서 갖춘 in vitro/in vivo assay를 대외적으로 서비스 함으로써 수요자들이 원하는 맞춤형 유효성 평가를 제공하고자 합니다.

MEMBER

상세소개

안희정 교수(센터장)

· 소속
병리과
· 연구분야
암 치료 표적 발굴,
암질환 바이오마커 발굴

상세소개

문용화 교수

· 소속
종양내과
· 연구분야
유방암, 부인암 외

Major Research Fields

  • 난소암 항암표적치료, 암 줄기세포, 바이오마커개발,
    면역세포치료제 개발
  • 항암제 초기 (1/2상) 임상시험, 환자 유래 마우스 항암평가 모델, 인간화마우스 모델, 항암 면역치료제 개발(작용 증강, 바이오마커)
  • 면역학, 유전체학

Publication

  • 1. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.

    Jeong JY, Kang H, Kim TH, Kim G, Heo JH, Kwon AY, Kim S, Jung SG, An HJ.
    Cancer Lett. 2017 Feb 1;386:168-178. doi: 10.1016/j.canlet.2016.11.017. Epub 2016 Nov 22.

  • 2. Sox10 expression in ovarian epithelial tumors is associated with poor overall survival.

    Kwon AY, Heo I, Lee HJ, Kim G, Kang H, Heo JH, Kim TH, An HJ.
    Virchows Arch. 2016 May;468(5):597-605. doi: 10.1007/s00428-016-1918-9. Epub 2016 Mar 7.

  • 3. PI3K/Akt/mTOR activation by suppression of ELK3 mediates chemosensitivity of MDA-MB-231 cells to doxorubicin by inhibiting autophagy.

    Park JH, Kim KP, Ko JJ, Park KS.
    Biochem Biophys Res Commun. 2016 Aug 19;477(2):277-82. doi: 10.1016/j.bbrc.2016.06.057. Epub 2016 Jun 11.

  • 4. The ELK3-GATA3 axis orchestrates invasion and metastasis of breast cancer cells in vitro and in vivo.

    Kong SY, Kim KS, Kim J, Kim MK, Lee KH, Lee JY, Oh N, Park JI, Park JH, Heo SH, Shim SH, Lee DR, Kim KP, Park KS.
    Oncotarget. 2016 Oct 4;7(40):65137-65146. doi: 10.18632/oncotarget.11427.

  • 5. Notch3-specific inhibition using siRNA knockdown or GSI sensitizes paclitaxel-resistant ovarian cancer cells.

    Kang H, Jeong JY, Song JY, Kim TH, Kim G, Huh JH, Kwon AY, Jung SG, An HJ.
    Mol Carcinog. 2016 Jul;55(7):1196-209. doi: 10.1002/mc.22363. Epub 2015 Jul 24.

  • 6. Fibulin-5 is a tumour suppressor inhibiting cell migration and invasion in ovarian cancer.

    Heo JH, Song JY, Jeong JY, Kim G, Kim TH, Kang H, Kwon AY, An HJ.
    J Clin Pathol. 2016 Feb;69(2):109-16. doi: 10.1136/jclinpath-2015-203129. Epub 2015 Aug 6.

  • 7. SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model.

    Kim G, Ouzounova M, Quraishi AA, Davis A, Tawakkol N, Clouthier SG, Malik F, Paulson AK, D'Angelo RC, Korkaya S, Baker TL, Esen ES, Prat A4, Liu S, Kleer CG, Thomas DG, Wicha MS, Korkaya H.
    Oncogene. 2015 Feb 5;34(6):671-80. doi: 10.1038/onc.2014.4. Epub 2014 Feb 17.

  • 8. miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma.

    Kim TH, Song JY, Park H, Jeong JY, Kwon AY, Heo JH, Kang H, Kim G, An HJ.
    Cancer Lett. 2015 Jan 28;356(2 Pt B):937-45. doi: 10.1016/j.canlet.2014.11.011. Epub 2014 Nov 10.

  • 9. VAV3 Overexpressed in Cancer Stem Cells Is a Poor Prognostic Indicator in Ovarian Cancer Patients.

    Kwon AY, Kim GI, Jeong JY, Song JY, Kwack KB, Lee C, Kang HY, Kim TH, Heo JH, An HJ.
    Stem Cells Dev. 2015 Jul 1;24(13):1521-35. doi: 10.1089/scd.2014.0588. Epub 2015 Apr 9.

  • 10. LAMC2 enhances the metastatic potential of lung adenocarcinoma.

    Moon YW, Rao G, Kim JJ, Shim HS, Park KS, An SS, Kim B, Steeg PS, Sarfaraz S, Changwoo Lee L, Voeller D, Choi EY, Luo J, Palmieri D, Chung HC, Kim JH, Wang Y, Giaccone G.
    Cell Death Differ. 2015 Aug;22(8):1341-52. doi: 10.1038/cdd.2014.228. Epub 2015 Jan 16.

  • 11. Differential expression of lipid metabolism-related proteins in different breast cancer subtypes.

    Kim S, Lee Y, Koo JS.
    PLoS One. 2015 Mar 9;10(3):e0119473. doi: 10.1371/journal.pone.0119473. eCollection 2015.

  • 12. Ell3 stabilizes p53 following CDDP treatment via its effects on ubiquitin-dependent and -independent proteasomal degradation pathways in breast cancer cells.

    Ahn HJ, Kim KS, Shin KW, Lim KH, Kim JO, Lee JY, Kim J, Park JH, Yang KM, Baek KH, Ko JJ, Park KS.
    Oncotarget. 2015 Dec 29;6(42):44523-37. doi: 10.18632/oncotarget.5972.

  • 13. Ell3 stabilizes p53 following CDDP treatment via its effects on ubiquitin-dependent and -independent proteasomal degradation pathways in breast cancer cells.

    Ahn HJ, Kim KS, Shin KW, Lim KH, Kim JO, Lee JY, Kim J, Park JH, Yang KM, Baek KH, Ko JJ, Park KS.
    Oncotarget. 2015 Dec 29;6(42):44523-37. doi: 10.18632/oncotarget.5972.

  • 14. Novel Function of Lysine Methyltransferase G9a in the Regulation of Sox2 Protein Stability.

    Lee J, Lee SH, Heo SH, Kim KS, Kim C, Kim DK, Ko JJ, Park KS.
    PLoS One. 2015 Oct 22;10(10):e0141118. doi: 10.1371/journal.pone.0141118. eCollection 2015.

  • 15. ELK3 Expression Correlates With Cell Migration, Invasion, and Membrane Type 1-Matrix Metalloproteinase Expression in MDA-MB-231 Breast Cancer Cells.

    Heo SH1, Lee JY, Yang KM, Park KS.
    Gene Expr. 2015;16(4):197-203. doi: 10.3727/105221615X14399878166276.

  • 16. Dysregulated microRNA expression in adenocarcinoma of the uterine cervix: clinical impact of miR-363-3p.

    Park H, Lee MJ, Jeong JY, Choi MC, Jung SG, Joo WD, Lee C, An HJ.
    Gynecol Oncol. 2014 Dec;135(3):565-72. doi: 10.1016/j.ygyno.2014.09.010. Epub 2014 Sep 16.

  • 17. Overexpression of goosecoid homeobox is associated with chemoresistance and poor prognosis in ovarian carcinoma.

    Kang KW, Lee MJ, Song JA, Jeong JY, Kim YK, Lee C, Kim TH, Kwak KB3, Kim OJ, An HJ.
    Oncol Rep. 2014 Jul;32(1):189-98. doi: 10.3892/or.2014.3203. Epub 2014 May 20.

  • 18. Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.

    Jeong JY, Kim KS, Moon JS, Song JA, Choi SH, Kim KI, Kim TH, An HJ.
    Apoptosis. 2013 Apr;18(4):509-20. doi: 10.1007/s10495-013-0807-9

  • 19. MicroRNAs overexpressed in ovarian ALDH1-positive cells are associated with chemoresistance.

    Park YT, Jeong JY, Lee MJ, Kim KI, Kim TH, Kwon YD, Lee C, Kim OJ, An HJ.
    J Ovarian Res. 2013 Mar 22;6(1):18. doi: 10.1186/1757-2215-6-18.

  • 20. S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial.

    Moon YW, Lee S, Park BW, Kim EK, Kim SI, Koo JS, Park S, Kim MJ, Chung HC, Kim JH, Sohn J.
    BMC Cancer. 2013 Dec 6;13:583. doi: 10.1186/1471-2407-13-583.

  • 21. Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.

    Jeong JY, Kim KS, Moon JS, Song JA, Choi SH, Kim KI, Kim TH, An HJ.
    Apoptosis. 2013 Apr;18(4):509-20. doi: 10.1007/s10495-013-0807-9.

  • 22. MicroRNAs overexpressed in ovarian ALDH1-positive cells are associated with chemoresistance.

    Park YT, Jeong JY, Lee MJ, Kim KI, Kim TH, Kwon YD, Lee C, Kim OJ, An HJ.
    J Ovarian Res. 2013 Mar 22;6(1):18. doi: 10.1186/1757-2215-6-18.

  • 23. S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial.

    Moon YW, Lee S, Park BW, Kim EK, Kim SI, Koo JS, Park S, Kim MJ, Chung HC, Kim JH, Sohn J.
    BMC Cancer. 2013 Dec 6;13:583. doi: 10.1186/1471-2407-13-583.

  • 24. Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer.

    Huh JH, Kim TH, Kim K, Song JA, Jung YJ, Jeong JY, Lee MJ, Kim YK, Lee DH, An HJ.
    Br J Cancer. 2013 Jul 23;109(2):452-61. doi: 10.1038/bjc.2013.305. Epub 2013 Jun 27.
논문 더보기+
top
CellTheP 세포치료제 R&BD 지원센터경기도 성남시 분당구 판교로 335 차바이오컴플렉스
COPYRIGHT (C) 2017 CHAMC. ALL RIGHTS RESERVED.